Herein, we report an interim analysis of the ongoing phase II trial, the COMBI study, evaluating safety and efficacy of CT with low‐dose PEG‐IFNα2 and ruxolitinib in 50 patients with PV or low‐/intermediate‐risk MF at 12 months of follow‐up. Here, IFNA2 is linked to acquired polycythemia vera.